Press Releases
Looking for more press releases? Explore our full press release archive by date to access past announcements, news updates, and media releases published on Technology Week Liechtenstein.
Prized ancient art and antiquities from estate of top British collector to highlight TimeLine's Sept. 9-13 auction
Opening session of 415 premier objects includes twice-life-size marble head of Hadrian, Egyptian panel showing Ptah with metalworkers, Mesopotamian torch bearer HARWICH, ESSEX, UNITED KINGDOM, September 2, 2025 /EINPresswire.com/ -- Britain’s...
argenx Announces European Commission Approval of VYVGART Subcutaneous Injection for Chronic Inflammatory Demyelinating Polyneuropathy
VYVGART® SC, first-and-only IgG Fc-antibody fragment which specifically targets the neonatal Fc receptor (FcRn), now approved for use in Europe for CIDP Approval based on ADHERE clinical trial, the largest study of CIDP patients to date First...
Dental Implants Market worth US$18.79 billion by 2030 with 8.4% CAGR | MarketsandMarkets™.
Delray Beach, FL, June 19, 2025 (GLOBE NEWSWIRE) -- The global dental implants market, valued at US$11.61 billion in 2024, stood at US$12.57 billion in 2025 and is projected to advance at a resilient CAGR of 8.4% from 2025 to 2030, culminating in...
European Commission Approves Duvyzat for the Treatment of Duchenne Muscular Dystrophy
Now approved in the EU, Duvyzat offers an important treatment option for delaying Duchenne muscular dystrophy (DMD) disease progression Duvyzat is an orally administered treatment for DMD in patients 6 years and older who are able to walk The...
Introducing Obyte City: A Community Space to Find Neighbors and Earn Rewards
Obyte City is a new community space for Obyte to strengthen connections between community members TRIESEN, LIECHTENSTEIN, June 3, 2025 /EINPresswire.com/ -- Obyte proudly unveils Obyte City, a cypherpunk-inspired digital space designed to...
Basilea reports presentation of new data for fosmanogepix, isavuconazole (Cresemba®) and ceftobiprole (Zevtera®) at ESCMID Global 2025
Allschwil, Switzerland, April 16, 2025 Basilea Pharmaceutica Ltd, Allschwil (SIX: BSLN), a commercial-stage biopharmaceutical company committed to meeting the needs of patients with severe bacterial and fungal infections, announced today...
OilXCoin's Prospectus Secures First Regulatory Approval For A Very Unique Security Token Backed by Oil & Gas
Geneva, Switzerland, April 08, 2025 (GLOBE NEWSWIRE) -- The Financial Market Authority (FMA) in Liechtenstein has approved the security prospectus for OilXCoin for offering in key EEA jurisdictions and establishing its presence in the Real-World...
LCX Strengthens Ties with Cardano Ecosystem, Launches Token Sale for Profila’s $ZEKE Token
Vaduz, Liechtenstein, Feb. 11, 2025 (GLOBE NEWSWIRE) -- LCX, a regulated and compliant crypto exchange, continues to expand its presence within the Cardano ecosystem by launching the token sale for Profila’s native token, $ZEKE. This collaboration...
Legacy Network Powers Up Education With Major Blockchain Move – $LGCT Set To Become Global Currency Of Learning
RUGGEL, Liechtenstein, March 28, 2025 (GLOBE NEWSWIRE) -- In a bold leap forward to redefine education worldwide, Legacy Network announces the expansion of it’s $LGCT token onto the Base blockchain. This strategic upgrade is poised to establish...
New Business Development through the Expansion of Swiss Security Solutions LLC's - Securely Swiss® Online Shopify Store
The first Swiss Security & Investigations Trademark Securely Swiss® is now on Shopify, selling a part of their security and intelligence services and solutions. ZURICH, ZURICH ZH, SWITZERLAND, August 13, 2025 /EINPresswire.com/ -- The first...
xPortal Acquires Alphalink to Drive Innovation at the Intersection of AI and Crypto
Vaduz, Liechtenstein, Jan. 24, 2025 (GLOBE NEWSWIRE) -- xPortal, the AI-powered DeFi super-app, has acquired Alphalink, a Berlin-based Web3 startup recognized for delivering delightfully simple crypto experiences through its mobile app. The...
argenx Announces Positive CHMP Opinion for VYVGART (efgartigimod alfa) Subcutaneous Injection for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
VYVGART® is first-and-only targeted IgG Fc-antibody fragment for CIDP First novel mechanism of action for CIDP treatment in more than 30 years CHMP positive opinion based on ADHERE data, the largest ever CIDP clinical trial European Commission...
Leqembi®∇ (lecanemab) is the First Medicine that Slows Progression of Early Alzheimer’s Disease to be Authorized in the European Union
In the European Union (EU), lecanemab is indicated for the treatment of adult patients with a clinical diagnosis of mild cognitive impairment and mild dementia due to Alzheimer’s disease (early AD) who are apolipoprotein E ε4 (ApoE ε4*)...
CariPower Becomes First Order Provider Chosen by Obyte’s Decentralized Governance
CariPower becomes the first Order Provider chosen by Obyte’s governance introduced in November 2024. Obyte is a fully decentralized DAG-based crypto network. VADUZ, LIECHTENSTEIN, March 25, 2025 /EINPresswire.com/ -- Obyte, a leading...
Radiance Biopharma Enters Exclusive License For ROR-1 Targeted Antibody Drug Conjugate
BOSTON, Massachusetts, Feb. 19, 2025 (GLOBE NEWSWIRE) -- Radiance Biopharma, Inc., ("Radiance" or the "Company"), a biotechnology company, today announced that it has entered into an exclusive License agreement with CSPC Megalith Biopharmaceutical...
Autolus Therapeutics’ CAR T Therapy AUCATZYL® (Obecabtagene Autoleucel) Granted European Marketing Authorization for Adult Patients (age 26 and older) with Relapsed or Refractory B-Cell Precursor Acute Lymphoblastic Leukemia (R/R B-ALL)
Approval is based on FELIX clinical trial of obecabtagene autoleucel (obe-cel) in adult patients with r/r B-ALL, demonstrating high and durable response rates and low toxicity EC approval follows positive CHMP opinion, MHRA conditional marketing...
4BIO Capital co-leads Actithera’s oversubscribed $75.5 million Series A financing
4BIO investing in unique radiopharmaceutical platform company, developing radioligands with prolonged tumour retention Series A was co-led by 4BIO Capital, founding investor M Ventures, Hadean Ventures, and Sofinnova Partners, with syndicate...
